BIHi005-A
General
Donor Information
General Donor Information |
|
Sex | male |
Age of donor (at collection) | 25-29 |
Ethnicity | asian |
Phenotype and Disease related information (Donor) |
|
Diseases | No disease was diagnosed.
|
Disease associated phenotypes | no phenotypes |
Family history | Mutation in the LMNA gene in other family members but not in this sample |
Karyotyping (Donor) |
|
Has the donor karyotype been analysed? |
Yes
Karyotyping method:
Molecular karyotyping by SNP array
http:// |
Other Genotyping (Donor) |
|
Is there genome-wide genotyping or functional data available? |
No
|
Donor Relations |
|
Other cell lines of this donor | |
All cell lines of this donor's relatives |
Has brother:
|
External Databases (Donor) |
|
BioSamples | SAMEA104012190 |
Ethics
Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
Was the consent voluntarily given? | Yes |
Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
Can you provide us with a copy of the Donor Information Sheet provided to the donor? | No |
Provide contact information of the holder of the original Donor Information Sheet: | liqunzhu@stanford.edu |
Do you (Depositor/Provider) hold the original Donor Consent Form? | Yes |
Is there other documentation provided to the donor for consenting purposes? | No |
Confirm that consent was obtained by a qualified professional | Yes |
Has the donor agreed to be re-contacted? | Unknown |
Has the donor been informed about how her/his data will be protected? | Yes |
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
Does consent expressly prevent the derivation of pluripotent stem cells? | No |
Does consent pertain to a specific research project? | No |
Does consent permit unforeseen future research, without further consent? | Yes |
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
Does consent permit research by | |
an academic institution? | Yes |
a public organisation? | Yes |
Does consent expressly permit collection of genetic information? | Yes |
Does consent expressly permit storage of genetic information? | Yes |
Does consent prevent dissemination of genetic information? | No |
How may genetic information associated with the cell line be accessed? | Controlled Access |
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? | No |
Does the consent permit the donor, upon withdrawal of consent, to stop delivery or use of information and data about the donor? | No |
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
Name of accrediting authority involved? | David Spiegel, M.D., Administrative Panel on Human Subjects in Medical Research Stanford University |
Approval number | 350 (Panel: 3) |
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? | Yes |
Name of accrediting authority involved? | David Spiegel, M.D., Administrative Panel on Human Subjects in Medical Research Stanford University |
Approval number | 350 (Panel: 3) |
Do you have obligations to third parties in regard to the use of the cell line? | No |
Are you aware of any further constraints on the use of the donated embryo/tissue or derived cells? | No |
Is there an MTA available for the cell line? | Yes |
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | Miltenyi mRNA reprogramming |
hIPSC Derivation
General |
|
Source cell type |
fibroblast of dermis |
Source cell origin |
zone of skinAny portion of the organ that covers that body and consists of a layer of epidermis and a layer of dermis.
|
Age of donor (at collection) | 25-29 |
Collected in | 2012 |
Reprogramming method |
|
Vector type | Non-integrating |
Vector | mRNA Miltenyi |
Is reprogramming vector detectable? |
No |
Methods used |
Immunostaining
|
Vector free reprogramming |
|
Other |
|
Derived under xeno-free conditions |
No |
Derived under GMP? |
No |
Available as clinical grade? |
No |
Culture Conditions
Surface coating | Matrigel/Geltrex |
Feeder cells |
No |
Passage method |
Enzyme-free cell dissociation
EDTA
|
O2 Concentration | 5 % |
CO2 Concentration | 5 % |
Medium |
Essential 8™
|
Has Rock inhibitor (Y27632) been used at passage previously with this cell line? | Yes |
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line? | No |
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line? | Yes |
Characterisation
Analysis of Undifferentiated Cells
Marker | Expressed | Immunostaining | RT-PCR | FACS | Enzymatic Assay | Expression Profiles |
POU5F1 (OCT-4) |
Yes |
|
||||
SOX2 |
Yes |
|
||||
SSEA-4 |
Yes |
|||||
TRA 1-60 |
Yes |
|
Differentiation Potency
In vitro directed differentiation
In vitro directed differentiation
Marker | Expressed |
platelet derived growth factor receptor beta |
Yes |
cadherin 5 |
Yes |
TnnT2 |
Unknown |
Microbiology / Virus Screening |
|
HIV 1 | Negative |
Hepatitis B | Negative |
Hepatitis C | Negative |
Mycoplasma | Negative |
Genotyping
Karyotyping (Cell Line) |
|
Has the cell line karyotype been analysed? |
Yes
|
Other Genotyping (Cell Line) |
Login to share your feedback, experiences or results with the research community.